进展期胃癌治疗药物的选择

被引:4
作者
李开春 [1 ]
李平 [2 ]
机构
[1] 同济大学附属天佑医院肿瘤科
[2] 第二军医大学长海医院消化内科
关键词
胃肿瘤; 药物疗法; 综述;
D O I
暂无
中图分类号
R979.1 [抗肿瘤、抗癌药物];
学科分类号
1007 ;
摘要
近年来,胃癌治疗取得很大进展,但其死亡率在癌症中仍居第三位。细胞毒类药物包括氟尿嘧啶类、紫杉类、第三代铂类药物和拓扑异构酶Ⅰ抑制剂在进展期胃癌化疗中应用,提高了病人生活质量,延长了总生存期,但存在生存期较短、药品不良反应等较多的弊端。随着胃癌发生、发展的分子机制逐步被认识,靶向药物曲妥珠单抗、雷莫芦单抗和阿帕替尼已经在临床应用。本文对进展期胃癌的治疗药物选择做一综述。
引用
收藏
页码:1 / 5
页数:5
相关论文
共 11 条
[1]  
Annual report on status of cancer in China, 2011[J]. Wanqing Chen,Rongshou Zheng,Hongmei Zeng,Siwei Zhang,Jie He. Chinese Journal of Cancer Research. 2015(01)
[2]  
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application[J] . Kaichun Li,Jin Li,Ralf-Dieter Hofheinz. Gastroenterology Research and Practice . 2016
[3]  
Global cancer statistics, 2012[J] . Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet‐Tieulent,Ahmedin Jemal. CA: A Cancer Journal for Clinicians . 2015 (2)
[4]  
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J] . Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang-Cheul Oh,Gy?rgy Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae-You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan
[5]  
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J] . Charles S Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,Giuseppe Aprile,David R Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Raymond Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Mi
[6]  
Ramucirumab: First Global Approval[J] . Raewyn M. Poole,Asha Vaidya. Drugs . 2014 (9)
[7]  
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis[J] . Koji Oba. European Journal of Cancer . 2012
[8]  
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study[J] . Akira Sawaki,Yasuo Ohashi,Yasushi Omuro,Taroh Satoh,Yasuo Hamamoto,Narikazu Boku,Yoshinori Miyata,Hiroya Takiuchi,Kensei Yamaguchi,Yasutsuna Sasaki,Tomohiro Nishina,Atsushi Satoh,Eishi Baba,Takao Tamura,Takashi Abe,Kiyohiko Hatake,Atsushi Ohtsu. Gastric Cancer . 2012 (3)
[9]  
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J] . Yung-Jue Bang,Eric Van Cutsem,Andrea Feyereislova,Hyun C Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,Giuseppe Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang. The Lancet . 2010 (9742)
[10]  
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer[J] . Ryu,Kang. Expert Review of Anticancer Therapy . 2009 (12)